Lund, Sweden, 10 June 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Fredrik Röök has been appointed as VP Business Development effective 17th August. Mr Röök will report to CEO Renée Aguiar-Lucander. Read more…
Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted therapies Barcelona, Spain – 10 June 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in […]
Sofinnova combines its sector expertise with AWS’s AI and cloud services to help life sciences companies scale faster The collaboration expands Sofinnova’s proprietary AI platform, Sofia, including a new founder-facing version PARIS, France – June 10, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, […]
Dalton is a drug discovery platform integrating agentic AI, human expertise, and experimental data, into one continuous learning engine Announces collaboration with Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), as a client London, UK – 4 June 2026 – DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and […]
Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer Financing supports Ona’s transition […]
